Skip to main content

Advertisement

SpringerLink
Log in

Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Anemia of chronic disease (ACD) is a frequent complication of chronic inflammation in rheumatoid arthritis (RA). Recombinant human erythropoietin (rHuEpo) has been shown to be effective in correcting ACD, although with a variable rate of nonresponders. The first aim of this trial was to improve the response to rHuEpo by parenteral iron supplementation in cases of iron-deficient erythropoiesis (IDE). An additional goal was the evaluation of the zinc protoporphyrin content of erythrocytes (ZnPP), the soluble transferrin receptor (sTrfR) serum concentration, and the hemoglobin (Hb) content of reticulocytes (CHr) in stimulated erythropoiesis as diagnostic and prognostic parameters. Thirty RA patients with ACD were treated with subcutaneous 150 IU rHuEpo/kg body weight twice weekly. Intravenous iron supplementation (200 mg iron sucrose once weekly) was added in cases of IDE (n=23), which was defined by the presence of two of three criteria: saturation of transferrin (TrfS) ≤15%, hypochromic erythrocytes (HypoE) ≥10%, and a serum ferritin (Fn) concentration ≤50 μg/l. All 28 completers met the treatment goal, with an increase of the median Hb concentration from 10.3 g/dl to 13.3 g/dl. Epo treatment and iron supplementation was safe and well tolerated in all patients. Monitoring of Fn, TrfS, and HypoE every other week allowed a successful correction of anemia. Retrospective analysis of the evaluable parameters (CHr, sTrfR, and ZnPP) revealed no additional benefit for predicting or monitoring IDE in this setting, although the one or other may be advantageous in other therapeutic situations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A (2000) J Am Soc Nephrol 11:530–538

    CAS  PubMed  Google Scholar 

  2. Blake DR, Lunec J, Ahern M, Ring EFJ, Bradfield J, Gutteridge JMC (1985) Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis 44:183–188

    CAS  PubMed  Google Scholar 

  3. Braun J (1999) Erythrocyte zinc protoporphyrin. Kidney Int 55:57–60

    Article  Google Scholar 

  4. Brugnara C, Colella GM, Cremis J, Langley RC, Schneider TJ, Rutherford CJ, Goldberg MA (1994) Effect of subcutaneous recombinant erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 123:660–667

    CAS  PubMed  Google Scholar 

  5. Cazzola M, Mercuriali F, Brugnara C (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood 12:4248–4267

    Google Scholar 

  6. Curt GA, Breithbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DEH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncology 5:353–360

    Article  CAS  Google Scholar 

  7. Demetri GD, Kris M, Wade J (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16:3412–4325

    CAS  PubMed  Google Scholar 

  8. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD (1992) Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med 19:385–390

    Google Scholar 

  9. Fishbane S, Frei GL, Maesaka J (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41–46

    CAS  PubMed  Google Scholar 

  10. Fishbane S, Galgano C, Langley RC, Canfield W, Maesaka JK (1997) Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 52:217–222

    CAS  PubMed  Google Scholar 

  11. Fitzsimmons EJ, Sturrock RD (2002) The chronic anaemia of rheumatoid arthritis: iron banking or blocking? Lancet 360:1713–1714

    Article  PubMed  Google Scholar 

  12. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145

    CAS  PubMed  Google Scholar 

  13. Garrett S, Worwood M (1994) Zinc protoporphyrin and iron-deficient erythropoiesis. Acta Haematol 91:21–25

    CAS  PubMed  Google Scholar 

  14. Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropietin. Oncology 13:461–473

    CAS  PubMed  Google Scholar 

  15. Glaspy J, Bukowski R, Steingerg D (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218–1234

    CAS  PubMed  Google Scholar 

  16. Goodnough LT, Skikne B, Brugnara C (2000) Erythropoietin, iron, and erythropoiesis. Blood 96:823–833

    CAS  PubMed  Google Scholar 

  17. Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R (1993) Zinc protoporphyrin in anemia of chronic disorders. Blood 81:1200–1204

    CAS  PubMed  Google Scholar 

  18. Jelkmann W (1998) Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 18:555–559

    CAS  PubMed  Google Scholar 

  19. Jensen NM, Brandsborg M, Boesen AM, Yde H, Dahlerup JF (1999) Low-dose oral iron absorption test in anaemic patients with and without iron deficiency determined by bone marrow iron content. Eur J Haematol 63:103–111

    Google Scholar 

  20. Jongen-Lavrencic M, Peeters HR, Wognum A, Vreugdenhil G, Breedveld FC, Swaak AJ (1997) Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. J Rheumatol 24:1504–1509

    CAS  PubMed  Google Scholar 

  21. Kaltwasser JP, Gottschalk R (1999) Erythropoietin and iron. Kidney Int 55:49–56

    Article  Google Scholar 

  22. Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Möller B (2001) Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 28:2430–2436

    CAS  PubMed  Google Scholar 

  23. Littlewood TJ (2001) Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol Oncol 19:19–30

    Article  CAS  PubMed  Google Scholar 

  24. Means RT (1999) Advances in the anemia of chronic disease. Int J Hematol 70:7–12

    PubMed  Google Scholar 

  25. Means RT, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, Stone WJ, O’Neil VL, Pincus T (1989) Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis Rheum 32:638–642

    PubMed  Google Scholar 

  26. Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, Avram MM (1997) Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEpo. Am J Kidney Dis 30:912–922

    CAS  PubMed  Google Scholar 

  27. Nordstroem D, Lindroth Y, Marsal L, Hafstroem I, Henrich C, Rantapää-Dahlqvist S, Engstroem-Laurent A, Fyhrquist F, Friman C (1997) Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis. Rheumatol Int 17:67–73

    Article  PubMed  Google Scholar 

  28. Peeters HRM, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJG (1996) Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 55:739–744

    CAS  PubMed  Google Scholar 

  29. Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include 28-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    CAS  PubMed  Google Scholar 

  30. Sunder-Plassmann G, Hoerl WH (1995) Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070–2076

    CAS  PubMed  Google Scholar 

  31. Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48:1066–1076

    CAS  PubMed  Google Scholar 

  32. Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health status survey (SF-36). 1. Conceptual framework and item selection. Med Care 30:473–483

    PubMed  Google Scholar 

  33. Weiss G (2002) Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 16:87–96

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We express our gratitude to Roche-Pharma (formerly Boehringer Mannheim) for providing rHuEpo (Neo-Recormon) and financial support.

Author information

Authors and Affiliations

  1. Medizinische Klinik III, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    U. Arndt, J. P. Kaltwasser, R. Gottschalk & D. Hoelzer

  2. Klinik für Rheumatologie, klinische Immunologie und Allergologie, Inselspital, Universitätsspital Bern, Freiburgstraße, 3010, Berne, Switzerland

    B. Möller

Authors
  1. U. Arndt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. P. Kaltwasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Gottschalk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Hoelzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Arndt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arndt, U., Kaltwasser, J.P., Gottschalk, R. et al. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Ann Hematol 84, 159–166 (2005). https://doi.org/10.1007/s00277-004-0950-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-004-0950-z

Keywords

Search

Navigation